# Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

> **NCT05744375** · PHASE2 · TERMINATED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 2 (actual)

## Conditions studied

- Locally Advanced Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT05744375
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-28
- **Primary completion:** 2025-07-17
- **Final completion:** 2025-07-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.
- **Last updated:** 2026-04-02

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05744375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05744375, "Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05744375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*